• 1. Program Office for Cancer Screening in Urban China, National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, P.R.China;
  • 2. Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, P.R.China;
  • 3. Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, P.R.China;
  • 4. Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, P.R.China;
  • 5. Key Laboratory of Evidence-Based Medicine and Knowledge Translation of Gansu Province, Lanzhou University, Lanzhou, 730000, P.R.China;
CHEN Jing, Email: cjshcsyc@126.com; DAI Min, Email: daimin2002@hotmail.com
Export PDF Favorites Scan Get Citation

The study appeared the comparison between CONSORT and CENT, and promoted the combination with GRADE and N-of-1 trial. Our objective is to further develop the method of N-of-1 trial and to widely use it in clinical researches of some diseases.

Citation: LI Jiang, ZHAI Jingbo, SHANG Hongcai, YANG Kehu, TIAN Jinhui, CHEN Jing, DAI Min. Level of evidence and reporting standard in N-of-1 trial. Chinese Journal of Evidence-Based Medicine, 2017, 17(5): 612-615. doi: 10.7507/1672-2531.201701074 Copy

  • Previous Article

    Nonfinancial conflict of interests: the current situation
  • Next Article

    The application of two random-effect models for dose-response meta-analysis